Results 111 to 120 of about 425,308 (294)

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

open access: yesMolecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak   +10 more
wiley   +1 more source

Rapid affinity optimization of an anti-TREM2 clinical lead antibody by cross-lineage immune repertoire mining

open access: yesNature Communications
We describe a process for rapid antibody affinity optimization by repertoire mining to identify clones across B cell clonal lineages based on convergent immune responses where antigen-specific clones with the same heavy (VH) and light chain germline ...
Yi-Chun Hsiao   +14 more
doaj   +1 more source

Comparative analysis of neutralization assays performed using live SARS-CoV-2 virus and pseudovirus to assess immunogenicity of a bivalent SARS-CoV-2 protein vaccine in humans

open access: yesFrontiers in Immunology
ObjectivesThe rapid emergence of SARS-CoV-2 prompted accelerated vaccine development, with neutralization assays serving as essential tools to evaluate vaccine-induced immune responses.MethodsA post-hoc analysis of a Phase I/II trial evaluated the ...
Cuige Gao   +10 more
doaj   +1 more source

Outsmarting Pathogens with Antibody Engineering. [PDF]

open access: yesAnnu Rev Chem Biomol Eng, 2023
Qerqez AN, Silva RP, Maynard JA.
europepmc   +1 more source

Complex wavefront engineering with disorder-engineered metasurfaces

open access: yes, 2017
Recently, complex wavefront engineering with disordered media has demonstrated optical manipulation capabilities beyond those of conventional optics.
Arbabi, Amir   +9 more
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Preclinical Characterization of Efficacy and Pharmacodynamic Properties of Finotonlimab, a Humanized Anti-PD-1 Monoclonal Antibody

open access: yesPharmaceuticals
Background/Objectives: Finotonlimab (SCTI10A) is a humanized anti-PD-1 antibody tested in Phase III trials for several solid tumor types. Methods: This study characterized the in vitro and in vivo efficacy, Fc-mediated effector function, and non-clinical
Yunqi Yao   +15 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

open access: yesMolecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary   +1 more
wiley   +1 more source

Immunogenicity Assessment of a 14-Valent Human Papillomavirus Vaccine Candidate in Mice

open access: yesVaccines
Background: Cervical cancer ranks as the fourth most common cancer affecting women globally, with HPV as the primary etiology agent. Prophylactic HPV vaccines have substantially reduced the incidence of cervical cancer.
Lei Bei   +13 more
doaj   +1 more source

Simplifying complex antibody engineering using machine learning. [PDF]

open access: yesCell Syst, 2023
Makowski EK, Chen HT, Tessier PM.
europepmc   +1 more source

Home - About - Disclaimer - Privacy